Clinical Trial Update: Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating glofitamab in combination with lenalidomide is underway for high-risk patients with relapsed or refractory mantle cell lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Columvi (glofitamab)
• Revlimid (lenalidomide)

Snippet

Sponsor: Peking University Third Hospital | Conditions: MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 2 | Status: RECRUITING